[Press release] Oncodesign: 2017 annual results

April 11, 2018

  • Operating revenue up 77% to €25.91 million
  • R&D spending doubled to €13.9 million
  • Solid operational execution and rigorous management of acquisitions despite various accounting and tax impacts
  • Cash position net of short-term debt of €9.8 million (excluding GSK payment of €7.9 million received in January 2018)
  • Full results of the radiotracer trial expected at the end of Q2 2018 with the possibility of directly entering Phase III


[Press Release] Oncodesign concludes a long term service-based partnership with ERYTECH in oncology

March 27, 2018

  • Oncodesign has become a key ERYTECH partner for conducting preclinical trials under its oncology research programs
  • The partnership aims to establish the mechanism of action and potential of ERYTECH’s eryaspase and erymethionase in the treatment of various solid tumors


[Congress] ITOC- Berlin - 19-21 March, 2018


Come & explore our in vivo and in vitro platforms:

> Translational human reconstituted immune system in cancer models

> In-vitro / in-vivo pharmacology of immune checkpoint inhibitors

> Translational cancer biomarkers

Here is a snapshot of our offerings!


By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.